Article

Practical biomarkers and robust multiplex models for the prediction of response to promising first-line chemotherapy: A theranostic study in metastatic ovarian cancer patients with residual peritoneal tumors

2023-01-12

Abstract excerpt

<title>Abstract</title><p><bold>Background:</bold>In advanced or metastatic ovarian cancer patients, the therapeutic impact of molecular targeted agents and immunotherapy is limited, and current chemotherapeutic algorithms are still far from personalized medicine.<bold/>We recently demonstrated that intraperitoneal carboplatin with dose-dense paclitaxel (ddTCip) therapy is a promising front-line chemotherapy even...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4923add1-197a-5e07-86a6-e0040fb6325a
DOI: 10.21203/rs.3.rs-2465306/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Practical biomarkers and robust multiplex models for the prediction of response to promising first-line chemotherapy: A theranostic study in metastatic ovarian cancer patients with residual peritoneal tumorsDOI 10.21203/rs.3.rs-2465306/v1Read

Practical biomarkers and robust multiplex models for the prediction of response to the promising first-line chemotherapy: A theranostic study in metastatic ovarian cancer patients with residual peritoneal tumorsSemantic proximity Read

Prediction of response to promising first-line chemotherapy in ovarian cancer patients with residual peritoneal tumors: Practical biomarkers and robust multiplex modelsSemantic proximity Read

Construction and Validation of a Platinum Sensitivity Predictive Model With Multiple Genomic Variations for Epithelial Ovarian CancerSemantic proximity Read

Predicting Response to Platin Chemotherapy Agents with Biochemically-inspired Machine LearningSemantic proximity Read

Identification of platinum-resistance related small GTPase binding signatures to predict the prognosis of ovarian cancer by machine learning and integrated bioinformatic analysesSemantic proximity Read

A Comprehensive Tumor Molecular Profile Analysis in Clinical Practice: A Single Center’s ExperienceSemantic proximity Read

Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours.Semantic proximity Read

Predicting responses to platin chemotherapy agents with biochemically-inspired machine learningSemantic proximity Read

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‐L1 expression in cancer patientsSemantic proximity Read

Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020.Semantic proximity Read

Prognostic impact of genomically matched therapy for solid cancers using real-world data from a provincial hospital in JapanSemantic proximity Read

Construction of a mitochondria genes-based model for prognosis prediction, drug guidance and immune feature analysis in ovarian serous cystadenocarcinomaSemantic proximity Read